MiR-486 as an effective biomarker in cancer diagnosis and prognosis: a systematic review and meta-analysis.

MiR-486 as an effective biomarker in cancer diagnosis and prognosis: a systematic review and meta-analysis.

Oncotarget. 2018 Mar 02;9(17):13948-13958

Authors: Jiang M, Li X, Quan X, Yang X, Zheng C, Hao X, Qu R, Zhou B

Abstract
Purpose: MiR-486 was found to be associated with cancer's diagnosis and prognosis. This meta-analysis aimed to investigate the potential effect of miR-486 on cancer detection and prognosis.
Materials and Methods: We searched PubMed, Cochrane library, Embase, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases to find all correlated articles. The STATA 11.0 was applied to estimate the pooled effects, heterogeneity and publication bias.
Results: The pooled sensitivity (SEN), specificity (SPE) and Area under the curve (AUC) were 82% (95% CI: 78-85%), 88% (95% CI: 83-92%) and 0.91 (95% CI: 0.88-0.93). Subgroup analysis indicated miR-486 from circulating samples exhibited higher diagnostic accuracy with the AUC was 0.90 (95% CI: 0.87-0.92) than miR-486 from other specimen with the AUC of 0.78 (95% CI: 0.75-0.82) and miR-486 obtained a better diagnostic value in the Asian population with the AUC of 0.94 (95% CI: 0.91-0.95) than the Caucasian and Caucasian/African population with the AUC of 0.80 (95% CI: 0.76-0.83) and 0.89 (95% CI: 0.86-0.91) respectively. MiR-486 obtained high value for the diagnosis of non-small cell lung cancer with SEN, SPE and AUC were 0.82 (95% CI: 0.0.77-0.87), 0.90 (95% CI: 0.84-0.94) as well as 0.92 (95% CI: 0.89-0.94) respectively. For the 7 prognostic tests, the pooled hazard ratio (HR) was 0.48 (95% CI: -0.13-1.08) for low versus high miR-486 expression.
Conclusions: This meta-analysis indicated that miR-486 can be used as ideal biomarkers in the cancer's diagnosis. However, Low miR-486 expression did not increase the risk of poor outcome.

PMID: 29568407 [PubMed]

https://ift.tt/2pD6d7Y